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Abstract 
Antibiotic resistance is a growing problem in both the developing world and industrialized 
nations.  Bacterial infections are no longer cleared with a single round of antibiotics.  The 
problem could be combated by discovering new pathways to target with drug treatment.  One 
such possible pathway involves elongation factor P (EF-P), a bacterial protein involved in the 
regulation of antibiotic resistance and survival in other cellular stress. The modification of EF-P 
with (R)-β-Lysine by the lysyl-tRNA synthetase paralog PoxA affects protein synthesis in the 
ribosome by relieving stalling during translation of polyproline stretches (7). In PoxA deletion 
strains, EF-P is not modified decreasing cell replication rate, cell survival to stressful conditions 
and virulence of Salmonella enterica.  By analyzing the contact surface between EF-P and PoxA 
and comparing it to the complex of a tRNA and an aminoacyl-tRNA synthetase, we were able to 
identify the novel interactions that could be a potential drug target.  Most of the conserved 
interactions in the EF-P and PoxA complex correspond to the acceptor arm of the tRNA, but 
many of the contacts are unique.  Through mutating amino acids involved in polar contacts 
between PoxA and EF-P and replacing them with alanine through site directed mutagenesis, it 
was determined which contacts (both novel and conserved) are important for EF-P recognition.  
This was measured by analyzing the aminoacylation kinetics using either EF-P or PoxA mutants.  
Our results suggest that recognition of EF-P by PoxA is mainly accomplished through binding of 
conserved amino acids that resemble the acceptor stem of a tRNA, but the arginine 235 contact 
may provide a target for antibiotic development. 
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Introduction 
Antibiotics have been in use for over 70 years and although their benefits are clear, the 
over and misuse of antimicrobials has led to the spread of multi-drug resistant pathogens (1,2).  
Pathogens are increasingly resistant to the available antibiotics,  which is complicated by 
hampered pharmaceutical development(2,3).  Thus, patients endure greater costs and longer 
hospital stays (3).   The demand for new antibiotics is clear, but scientists face the problem of 
discovering a new, effective pathway to target.  Since most of the obvious antibiotics, like 
penicillins, which disrupt external features like cell walls, have already been produced, scientists 
instead focus on new targets for drugs (2). 
Elongation factor P (EF-P) is a bacterial protein that is found in all bacteria and is an 
ortholog of the eukaryotic and archaeal initiation factor 5a.  It is required for pathways involved 
in antibiotic resistance and motility.  It is additionally important in survival under stress 
conditions created by S-nitroso-glutathione (GNSO) that mimics the nitric oxide burst seen in 
phagocytes (4).  EF-P, a structural and functional mimic of tRNA, is aminoacylated in vivo by 
the protein PoxA (previously named GenX or YjeA) with (R)-β-Lysine at the K34 modification 
site (5).  Modified EF-P has been shown to prevent ribosome stalling during the translation of 
sequential proline codons by restoring the activity of the ribosome that is disrupted by the 
polyproline stretch (6).  In the absence of EF-P, proteins with a series of three or more prolines 
are truncated during translation (7).  The modification of EF-P with (R)-β-Lysine is essential for 
the high efficiency of this function (6).  Proteins with a three or more consecutive prolines make 
up about 7% of the Escherichia coli genome and include proteins such as the flagellar proteins 
(FlhC, FliF, Flk), explaining EF-P’s effect on cellular motility, TonB, a protein that provides 
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energy for cellular transporters, and EspF which is an E.coli virulence protein of 
enterohaemorrhagic strains (7). 
PoxA, that aminoacylates EF-P with (R)-β-Lysine, is a paralog of the catalytic domain of 
lysyl-tRNA synthetase(LysRS)(8).  As both PoxA and EF-P are essential for determining 
virulence, motility and survival during cellular stress, we propose the PoxA EF-P aminoacylation 
reaction as a potential target for antibiotic development.   
In order to determine if there are any sites of PoxA where EF-P binds different than 
tRNA binds to aaRS, the contacts of EF-P and PoxA were identified and the polar amino acid 
contacts of PoxA were mutated to alanine.  The effect of the mutations on the aminoacylation of 
EF-P was measured and revealed that most of the important interactions between PoxA and EF-P 
are equivalent to the ones that bind to the acceptor stem of tRNA.  One of these contacts that is 
important for EF-P recognition has no corresponding contact in either the Saccharomyces 
cerevisiae aspartyl-tRNA synthetase (AspRS) or the Human lysl-tRNA synthetase (LysRS), 
suggesting a potential antimicrobial target.  
Results 
Only part of the AspRS/tRNA
Asp
 contacts are conserved on EF-P/PoxA complex 
To identify the contacts that evolved to recognize protein instead of RNA and which 
amino acids were conserved, the PoxA EF-P contacts were compared to the aspartyl-tRNA 
synthetase/tRNA
Asp
(AspRS/tRNA
Asp
) complex. An AspRS crystal structure was used instead of 
LysRS because the tRNA in complex with LysRS is not well resolved.  Because AspRS and 
LysRS are both sub-class 2b synthetases and have structural homology, AspRS is a logical 
substitute.  In comparing to the AspRS/tRNA
Asp
 system, many of the contacts between EF-P and 
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PoxA are unique, most likely due to the lack of the anticodon binding domain in PoxA which is 
responsible for most of tRNA binding energy by aminoacyl-tRNA synthetases (H52, D177, 
N180, E185, Q193,S218, R235, E244) (Figure 1).  There are some contacts that are highly 
conserved and those amino acids are the ones that contact the acceptor arm (E103, R106, H108).   
Analysis of the exchange of each of the EF-P/PoxA contacts 
In order to analyze the recognition of EF-P by PoxA, 11 mutants were constructed that 
exchanged to alanine amino acids making direct polar contacts.  To compare the effects of the 
mutations and therefore the importance of the contacts, the aminoacylation of EF-P with 
14
C -
lysine was measured for all mutants and compared to wild type PoxA (Table 1).  Some mutations 
had little or no effect on aminoacylation (Q193A, S218A, R106A, D177A), while some 
mutations reduced aminoacylation by half (H52A, N180A, E185A).  The mutations that 
completely inhibit aminoacylation of EF-P are the contacts that interact with EF-P’s structural 
mimic of the acceptor stem of tRNA (E103, H108, R235). 
These results were confirmed by aminoacylation experiments performed with the natural 
substrate of PoxA ((R)-β-Lysine).  Since we lack access to radioactive (R)-β-Lysine , EF-P was 
tagged with a cAMP dependent protein kinase A (pka) site to make 
32
P radiolabelled EF-P.  
Because aminoacylated EF-P and non-aminoacylated EF-P have different isoelectric focusing 
points, they were separated on an isoelectric focusing gel with a 4.5 to 5.4 pH gradient.  The 
radiolabelled EF-P allows for quantification by phosphor imaging, and this phosphorylation does 
not interfere with the aminoacylation reaction. These experiments confirmed the results of the 
14C α-Lysine experiments (Table 1)(9). 
Comparing the important contacts to AspRS/tRNA
Asp
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Only one of the polar contacts studied has a drastic effect on aminoacylation and has no 
corresponding contact in the AspRS/tRNA
Asp
 system (R235).  Although this residue is conserved 
in the LysRS synthetase (R485), the crystal structure superimposed upon the AspRS/tRNA
Asp
 
complex of S. cerevisiae indicates that it is not a contacting the tRNA (Figure 2).  The shortest 
distance between R485 and the tRNA is 9.14 Å. 
In order to confirm that these polar contacts are important for recognition by PoxA, the 
corresponding amino acids on the acceptor stem mimic of EF-P (F29, K31, G33), or the identity 
elements, were mutated to alanine.  The exchange of any of these residues almost completely 
prevents aminoacylation by PoxA indicating that these residues are all individually important for 
recognition (Figure 3). 
Discussion 
Our results show that recognition of EF-P by PoxA is mainly accomplished through 
binding of amino acids that resemble the acceptor stem of a tRNA. Most of the contacts are 
novel compared to the AspRS/tRNA
Asp
 system; nevertheless, the contacts that are important for 
PoxA recognition are both previously existing contacts that have an enhanced binding 
importance(E103, H108) and one of the new contacts (R235), all of which are interacting with 
EF-P identity elements.  These identity elements correspond to the CCA of the acceptor stem of 
a tRNA (Figure 4).   
EF-P PoxA contacts were compared to the AspRS/tRNA
Asp
 system, to identify a potential 
drug target.  Novel contacts would be the most ideal for a drug that targets bacteria to avoid host 
cell damage.  Since PoxA evolved from a lysyl-tRNA synthetase, the potential for a PoxA 
inhibitor to also block host LysRS must be considered.  The EF-P and PoxA contacts were 
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compared to the sequence of human AspRS, LysRS and AsnRS and only LysRS conserves the 
corresponding R235 residue (Figure 5).  In S. cerevisiae, the corresponding amino acid is a 
serine, rather than arginine, but the crystal structure of the AspRS/tRNA
Asp
(8,) shows that serine 
avoids tRNA contact (Figure 2). This position on PoxA is a possible target for blocking 
aminoacylation of EF-P in pathogenic bacteria that would likely not interfere with 
aminoacylation by Human LysRS.  Further experiments need to be done to confirm this. 
Scientists are focusing on finding new targets for antibiotic development to combat 
resistance.  Targets can be easily identified with genetic screening, but the actual development 
process takes years (10).  Thus, the many targets that have been identified, like EF-P, require 
assays to determine the site, compound and efficiency of an inhibitor.  Understanding the 
interactions between PoxA and EF-P helps to identify the residues that are important for 
recognition and is the first step in finding a binding site of a PoxA inhibitor.   
Materials and Methods 
Bioinformatic Analysis 
The contact surface between PoxA and EF-P was analyzed using the program 
PDBe/PISA
5 
with the crystal structure of the complex (pdb3A5Z).  Polar contacts previously 
described were also included in structure analysis(8).  Images were made with The PyMOL 
Molecular Graphics System (Version 1.2.0.3 Schrödinger, LLC) and Swiss-PdbViewer (Version 
4.0.4).  Sequence alignment was performed using COBALT. 
Mutagenesis of PoxA and EF-P 
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Both EF-P and PoxA mutations were performed by the Stratagene QuickChange Site 
Directed Mutagenesis protocol as suggested by the manufacturer (Stratagene).  Briefly, EF-P 
pTYB11 or PoxA pTYB11 were amplified with primers of tables 3 or 4.  Using a thermocycler  
with a melting temperature of 95
o
C and an annealing temperature of 55
o
C,  the primers annealed 
to the plasmid at the site of mutation and pfu DNA polymerase extended the primer, replicating 
the DNA completely, leaving a nick at the end. After digestion of the methylated (unmutated 
DNA) with DpnI, the amplified DNA was transformed in E.coli XL1Blue cells, which repaired 
both nicks that remained in the plasmid.   
Plasmid sequences were confirmed through sequencing at the Plant-Microbe Genomics 
Facility (PMGF) at The Ohio State University and then transformed in E. coli BL21 XJB (DE3) 
cells for overexpression in autoinduction media containing metal mix (50 nM FeCl3, 20 nM 
CaCl2, 10 nM MnCl2, 2 nM CuCl2, 2 nM NiCl2, 2 nM H3BO3), NPS (50mM Na2HPO4, 50 mM 
KH2PO4, 25 mM (NH4)2SO4), 5052 (0.025% glycerol, 0.0025% glucose and 0.01% lactose) and 
1mM MgSO4).   
Purification of EF-P, PoxA and mutant proteins 
Purification of all proteins was performed using chitin columns as previously described
4
 
Briefly, cells were resuspended in buffer A (50 mM Tris HCl pH 8.0, 500 mM NaCl and 10% 
glycerol) plus 0.05% triton X-100 and lysed by sonication with 0.75 mM PMSF. Cell debris was 
eliminated by centrifugation (70 min at 75600g) and the supernatant loaded to a chitin column. 
The column was washed with 5 volumes of buffer A plus 0.05% triton X-100 and then with 25 
volumes of buffer A. Finally the column was washed with 2 volumes of buffer A plus 100 mM 
DTT to stimulate digestion and incubated overnight at 4ºC.  The protein was eluted with buffer A 
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and concentrated using filter centrifugation unit MWCO of 3 KDa. Then the protein was 
dialyzed against dialysis buffer (25 mM Tris HCl pH 8.0, 150 mM NaCl and 4 mM 2-
mercaptoethanol) plus 50 % glycerol and stored at -20ºC. EF-P used for kcat/KM determinations 
was further purified through anion exchange using a Resource Q column. Protein was loaded on 
the column and washed with 10 volumes of Buffer 1 (25 mM Tris HCl pH8, 50 mM NaCl and 2 
mM 2-mercaptoethanol), then with additional 6 volumes of 10% Buffer 2 (25 mM Tris HCl pH8, 
1 M NaCl and 2 mM 2-mercaptoethanol) in Buffer 1. Finally the protein was eluted in a linear 
gradient to 14% Buffer 2 in Buffer 1, concentrated and dialyzed against dialysis buffer plus 20% 
glycerol. The protein was then stored aliquoted at -80ºC. All proteins were quantified in 6M 
guanidinium HCl using absorbance 280 and a molar extinction coefficient of 24750 M
-1
 cm
-1
 
(EF-P) or 29870 M
-1
 cm
-1
 (PoxA) which were calculated using EMBOSS (10). 
Aminoacylation with 
14
C -Lysine 
In order to obtain relative activity data, EF-P aminoacylation by the PoxA mutants was measured 
with 
14
C -Lysine.  Although -Lysine is not the natural substrate of PoxA[ref],  EF-P is still 
aminoacylated but at a much higher Km.  This reaction was performed in a mixture containing 
100mM glycine pH 9.0, 30 mM KCl, 10 mM MgCl2, 8 mM ATP pH 7.0, 3 mM -
mercaptoethanol, 8.36 U/mL pyrophosphotase and 0.75M or 10 M EFP.  At defined time 
points, aliquots were taken and either stopped by mixing with SDS-PAGE loading buffer or 
precipitated on 5% trichloroacetic acid saturated 3MM Whatman paper.  Papers were washed at 
RT with 5% tichloroacetic acid 3 times, for five minutes each, once with ethanol and dried at 
~85 ºC.  The 
14
C  aminoacylated EF-P was quantified using scintilation counting.  Aliquotes of 
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the reaction were separated in a SDS-PAGE and 
14
C -Lysyl EFP was detected by phosphor 
imaging. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11  
 
Figures 
Figure 1: Contact surface in EF-P/PoxA and AspRS/tRNA
Asp
 complexes.  Image corresponds 
to a superposition of AspRS and PoxA from pdb files 1asy and 3a5z.  A) AspRS in blue, PoxA 
in magenta. B) EF-P in light green and tRNA
Asp
 light orange.  
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Table 1: Effect of mutations on aminoacylation activity of PoxA and AspRS. *Data taken 
from Eriani and Gangloff (11). *1 From α-Lysine experiments *2 From R-β-Lysine 
experiments(9). Residues highlighted in red are important for EF-P recognition. 
Position 
mutated 
in PoxA 
from 
E.coli  
Corresponding 
position in 
Yeast AspRS  
kcat ratio 
mut/WT 
For Yeast 
AspRS*  
Effect on 
amino 
acid 
activation  
Mutant 
activity/ 
wildtype 
activity*1  
kcat/Km   
(μM-1 s-1)*2  
kcat/Km 
ratio 
mut/WT*2  
H52A Gap -  Active  0.56 0.013 1.11 
E103A S329 (G73 + 
C74)  
1.29 Active  <0.6 Inactive  ---  
R106A T331 (G73)  0.61 Reduced  0.62 0.011 0.23 
H108A H334 (C74)  0.12 Active  <0.6 Inactive  ---  
D177A Gap  - Active  0.69 0.027 0.53 
N180A Gap  - Active  0.52 0.041 0.82 
E185A Gap  - Active  0.44 0.013 0.27 
Q193A D421 -  Active  0.75 0.05 1 
S218A E451  - Active  0.96 0.047 0.93 
R235A S469  - Reduced  <0.6 Inactive  ---  
E244A E478  - Inactive  0.04 Inactive  ---  
Wildtype     1   
neg    0.06   
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Figure 2: Contact surface of Human LysRS/tRNA
Asp
 and S. cerevisiae AspRS/tRNA
Asp
.  
Image corresponds to a superimposition of pdb files 1asy and 4dpg.  S. cerevisiae AspRS is 
highlighted in red, Human LysRS in yellow and tRNA
Asp
 in purple.  S469 residue in S.cerevisiae 
(blue) and R485 residue in Human LysRS (black) that corresponds to R235 in PoxA do not 
contact the tRNA.  There is a distance of at least 9.14 Å between R485 from Human LysRS to 
tRNA. 
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Figure 3: Mutating F29, K31 or G33 of EF-P to alanine blocks its recognition by PoxA. 
Circles indicate wildtype EF-P, squares indicate the EF-P F29A mutant, diamonds are K31A and 
triangle is G33A 
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Figure 4: EF-P identity elements. Active site of PoxA. Green is EF-P, purple is PoxA. PoxA 
amino acids in which mutation abolished EF-P aminoacylation as well as the corresponding EF-
P contacts are highlighted.  These residues contact EF-P at the modification site. 
 
 
 
Figure 5: Alignment of amino acid sequences between synthetases.  The amino acid 
responsible for the novel interaction that is important in EF-P recognition by PoxA (R235) R235 
is only conserved in the Human Lysyl-tRNA synthetase.  Corresponding amino acids are 
highlighted in red. 
S. cerevisiae AspRS 467  SNSYDFFMRG-EEILSGAQRIHDHALLQE 
Human AspRS  413  SNSYDMFMRG-EEILSGAQRIHDPQLLTE 
Human AsnRS  459  TESVDVLMPNVGEIVGGSMRIFDSEEILA 
Human LysRS  483  TERFELFVMK-KEICNAYTELNDPMRQRQ 
E.coli PoxA  233  AERFEVYYKG-IELANGFHELTDAREQQQ 
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Table 3. Primers used for PoxA mutagenesis. 
 
 
Name Sequence *
1 Position mutated 
to alanine 
   
mut_His52Ala_fd GCGACGGTAACCGATATTgcTTTGGTCCCGTTTGAGACAC His52 
mut_His52Ala_rv GTGTCTCAAACGGGACCAAAgcAATATCGGTTACCGTCGC His52 
mut_Glu102Ala_fd CGCAGCTTCCGTAATGcAGAGATGGGGCGTTATC Glu102 
mut_Glu102Ala_rv GATAACGCCCCATCTCTgCATTACGGAAGCTGCG Glu102 
mut_Glu103Ala_fd CAGCTTCCGTAATGAAGcGATGGGGCGTTATCAC Glu103 
mut_Glu103Ala_rv GTGATAACGCCCCATCgCTTCATTACGGAAGCTG Glu103 
mut_Arg106Ala_fd CCGTAATGAAGAGATGGGGgcTTATCACAACCCTGAGTTCAC Arg106 
mut_Arg106Ala_rv GTGAACTCAGGGTTGTGATAAgcCCCCATCTCTTCATTACGG Arg106 
mut_His108Ala_fd GAAGAGATGGGGCGTTATgcCAACCCTGAGTTCACTATGC Hist108 
mut_His108Ala_rv GCATAGTGAACTCAGGGTTGgcATAACGCCCCATCTCTTC Hist108 
mut_Asp177Ala_fd GTCGCAGCGAAACTGGcTTTGAGCAATGTTGCTG Asp177 
mut_Asp177Ala_rv CAGCAACATTGCTCAAAgCCAGTTTCGCTGCGAC Asp177 
mut_Asn180Ala_fd CAGCGAAACTGGATTTGAGCgcTGTTGCTGATACCGAAGAAG Asn180 
mut_Asn180Ala_rv CTTCTTCGGTATCAGCAACAgcGCTCAAATCCAGTTTCGCTG Aspn180 
mut_Glu185Ala_fd CAATGTTGCTGATACCGcAGAAGACCGCGACACG Glu185 
mut_Glu185Ala_rv CGTGTCGCGGTCTTCTgCGGTATCAGCAACATTG Glu185 
mut_Gln193Ala_fd GACCGCGACACGCTGCTAgcATTGCTGTTTACCTTTGGC Gln193 
mut_Gln193Ala_rv GCCAAAGGTAAACAGCAATgcTAGCAGCGTGTCGCGGTC Gln193 
mut_Ser218Ala_fd GTACCACTTTCCAGCCgcCCAGGCATCACTGGCG Ser218 
mut_Ser218Ala_rv CGCCAGTGATGCCTGGgcGGCTGGAAAGTGGTAC Ser218 
mut_Arg235Ala_fd CGAAGATCATCGGGTCGCTGAAgcCTTTGAGGTTTATTATAAAGG Arg235 
mut_Arg235Ala_rv CCTTTATAATAAACCTCAAAGgcTTCAGCGACCCGATGATCTTCG Arg235 
mut_Glu244Ala_fd GGTTTATTATAAAGGTATTGcGCTGGCGAATGGTTTCCATG Glu244 
mut_Glu244Ala_rv CATGGAAACCATTCGCCAGCgCAATACCTTTATAATAAACC Glu244 
mut_Arg303Ala_fd GTGGCATTAGGTGTTGATgcTCTGGTGATGTTGGCGCTG Arg303 
mut_Arg303Ala_rv CAGCGCCAACATCACCAGAgcATCAACACCTAATGCCAC Arg303 
 
*
1
 Mutation site is marked in lower case. 
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Table 4. Primers used for EF-P mutagenesis. 
 
 
Name Sequence *
1 Position mutated 
to alanine 
   
mut_Phe29Ala_rv CCTTTACCCGGTTTTACGGCTTCACTCGCTTCAACCGG Phenylalanine 29 
mut_Phe29Ala_fd CCGGTTGAAGCGAGTGAAGCCGTAAAACCGGGTAAAGG Phenylalanine 29 
mut_Lys31Ala_rv CCTGGCCTTTACCCGGTGCTACGAATTCACTCGCTTC Lysine 31 
mut_Lys31Ala_fd GAAGCGAGTGAATTCGTAGCACCGGGTAAAGGCCAGG Lysine 31 
mut_Gly33Ala_rv GCAATGCCTGGCCTTTAGCCGGTTTTACGAATTCAC Glycine 33 
mut_Gly33Ala_fd GTGAATTCGTAAAACCGGCTAAAGGCCAGGCATTTGC Glycine 33 
 
*
1
 Mutation site is marked in lower case. 
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